Home » Biologics CDMO » Bioanalytical » SARS-CoV-2 Neutralizing Antibody In Vitro Bioassay Services

MOA of SARS-CoV-2 Binding Assay (ELISA)

Binding of His-RBD protein and neutralizing antibody.

Case Study

Note:

  1. ACE2-Fc was used as reference standard (RS).
  2. Both of RS and QC (quality control) were ACE2-Fc.

MOA of SARS-CoV-2 Neutralizing Assay (Cell-based ELISA)


  • (A) Binding of His-ECD protein and HeLa/ACE2 cells.
  • (B) Neutralization of ECD-HeLa/ACE2 binding by neutralizing antibody.

Case Study

Note:

  1. ACE2-Fc was used as reference standard (RS).
  2. Both of RS and QC (quality control) were ACE2-Fc.
  3. Human IgG1 (hIgG1) was used as a negative control.

B. Pseudo-virus neutralization assay. The neutralizing activity to protect target cells from being infected is the most important biological characterization of the neutralizing antibody. GenScript ProBio has developed a pseudo-virus neutralization assay according to the mechanism of action (MOA) of neutralizing antibodies as well as the SARS-CoV-2 infection.

C. Fc activity assays. The Fc activity is also the biological characterization of the product and also necessary in IND application. GenScript ProBio has developed related assays and only needs to verify the assay before sample testing, whereas full method qualification is not required. The assays include ADCC, CDC, and ELISA binding to Fc receptors (CD16a, 158V; CD16a, 158F; CD32a, 131H; CD32a, 131R; CD64; C1q; FcRn).